Category: 2022

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma C

Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated …

Read on
Experimental and in silico analysis of TEM beta lactamase adaptive evolution E

Standley M, Blay V, Beleva Guthrie B, Kim J, Lyman A, Moya A, Karchin R, Camps M. (2022) Experimental and in silico analysis of TEM beta lactamase adaptive evolution”. ACS Infectious Diseases 8(12):2451-63

Read on
Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria C

Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, O’Donnell-Luria A, Harrison SM, Tavtigian SV, Greenblatt MS, Biesecker LG, Radivojac P, Brenner SE; ClinGen Sequence Variant Interpretation Working Group. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Am J Hum Genet. 2022 Dec 1;109(12):2163-2177. doi: …

Read on
Pan-Cancer HLA Gene-mediated Tumor Immunogenicity and Immune Evasion Mol Cancer P

Gong X, Karchin R. Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune Evasion. Mol Cancer Res. 2022 Aug 5;20(8):1272-1283. doi: 10.1158/1541-7786.MCR-21-0886. PMID: 35533264; PMCID: PMC9357147.

Read on
Sex-specific differences in immunogenic features of response to immune checkpoint blockade S

Scott SC, Shao XM, Niknafs N, Balan A, Pereira G, Marrone KA, Lam VK, Murray JC, Feliciano JL, Levy BP, Ettinger DS, Hann CL, Brahmer JR, Forde PM, Karchin R, Naidoo J, Anagnostou V. (2022) Sex-specific differences in immunogenic features of response to immune checkpoint blockade Front Oncol. 2022 Aug;12:945798.

Read on
Estimation of cancer cell fractions and clone trees from multi-region sequencing of tumors E

Zheng L, Niknafs N, Wood LD, Karchin R, Scharpf RB. Estimation of cancer cell fractions and clone trees from multi-region sequencing of tumors. Bioinformatics. 2022 Aug 2;38(15):3677-3683. doi: 10.1093/bioinformatics/btac367. PMID: 35642899; PMCID: PMC9344857.

Read on
HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade H

Shao XM, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu VE, Anagnostou V, Karchin R. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Ann Oncol. 2022 Jul;33(7):728-738. doi: 10.1016/j.annonc.2022.03.013. Epub 2022 Mar 23. Erratum in: Ann Oncol. 2023 Jul;34(7):634. PMID: 35339648; PMCID: PMC10621650.

Read on